AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2011
Feb 3, 2011
30016_dirs_2011-02-03_e11f0232-98ec-4ef2-96e1-6243d8fffe5e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2011-02-01
Reporting Person: NAQUI ALI (Corporate Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-02-01 | Common Stock | M | 3678 | $28.655 | Acquired | 19686 | Direct |
| 2011-02-01 | Common Stock | M | 3230 | $25.45 | Acquired | 22916 | Direct |
| 2011-02-01 | Common Stock | S | 1678 | $72.2403 | Disposed | 21238 | Direct |
| 2011-02-01 | Common Stock | S | 3230 | $72.2111 | Disposed | 18008 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-02-01 | Incentive Stock Option (right to buy) | $28.655 | M | 3678 | Disposed | 2015-02-02 | Common Stock (3678) | Direct |
| 2011-02-01 | Non-Qualified Stock Option (right to buy) | $25.45 | M | 3230 | Disposed | 2014-02-04 | Common Stock (3230) | Direct |
Footnotes
F1: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $72.22 to $72.2746, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $72.21 to $72.235, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
F3: Grant of options to buy shares of common stock becomes exercisable as to 1,358 shares on 2/3/2009 and the remaining 2,320 shares on 2/3/2010.
F4: Grant of options to buy shares of common stock becomes exercisable as to 2,400 shares on 2/5/2005, 2/5/2006 and 2/5/2007, and the remaining 1,030 shares on 2/5/2008.